Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia.

N Valizadeh

Outlines

Abstract
Copyright

Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia.

Author(s):

N Valizadeh ^1,*

1Assistant Professor, Section of Hematology and Medical Oncology, Department of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Shiraz E-Medical Journal:Vol. 12, issue 3; 162-4

Published online:Jul 01, 2011

Article type:Research Article

Received:Dec 24, 2010

Accepted:May 03, 2011

How to Cite:N Valizadeh Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia..Shiraz E-Med J.12(3):162-4.

Abstract

Background:

Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic myelogenous leukemia (CML) and c-kit in patients with gastrointestinal stromal tu-mors (GISTs). Skin hypopigmentation is reported during Imatinib therapy. We present a case of CML who developed skin hyperpigmentation in the face during treatment with Imatinib which found chloasma-like appearance.

Keywords

Full Text

Full text is available in PDF

comments